great point and it makes sense.This is one of the ignores that put up conjecture and distortion.The company has stated there will be 30-50 patients as far as I know and the revenues over a million a quarter.If anyone has PROVEN information please post a link to statements not postings from a spam MB.The Italian government is analyzing the data of the above patient number which may not seem large but look at the size of the Phase3 Short stature trial.That data(current Italy) will be used as a possible basis of a better stuctured trial.The "big revenues" are small and should not be what is focused on (after getting their cut).The results will be the big story.
"Some 50 people with ALS in Italy are receiving Iplex through Insmed�s �expanded access� program"
March 7, 2007 Italians With ALS Gain Access to Drug The Italian Ministry of Health recently asked Insmed, a Richmond, Va., biopharmaceutical company, to make its drug Iplex available to amyotrophic lateral sclerosis (ALS) patients in Italy. The request has been granted.
Iplex is a combination of insulin-like growth factor 1 (IGF1) and IGF binding protein 3. It�s approved by the U.S. Food and Drug Administration to treat certain types of growth failure in children, and it�s also being tested in people with myotonic muscular dystrophy
Almost all IGF1 that circulates in the bloodstream is attached to IGF binding protein 3, so the combination may be a better mimic of human physiology than IGF1 alone.
IGF1 is being tested alone in a large-scale, multicenter trial in ALS, for which data analysis is scheduled to begin this summer. That compound, known as Myotrophin, failed to meet criteria for FDA approval in two earlier trials.
Some 50 people with ALS in Italy are receiving Iplex through Insmed�s �expanded access� program. �We hope data collected from the Italian patients who are participating in this expanded access program will be useful for further clinical development of Iplex and/or IGF1 for this indication,� said Geoffrey Allan, president and CEO of Insmed.